[go: up one dir, main page]

WO2024139647A1 - Vaccin à adn de papillomavirus humain de type 16 et son utilisation - Google Patents

Vaccin à adn de papillomavirus humain de type 16 et son utilisation Download PDF

Info

Publication number
WO2024139647A1
WO2024139647A1 PCT/CN2023/128073 CN2023128073W WO2024139647A1 WO 2024139647 A1 WO2024139647 A1 WO 2024139647A1 CN 2023128073 W CN2023128073 W CN 2023128073W WO 2024139647 A1 WO2024139647 A1 WO 2024139647A1
Authority
WO
WIPO (PCT)
Prior art keywords
plasmid
piss14
seq
dna vaccine
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/128073
Other languages
English (en)
Chinese (zh)
Inventor
许雪梅
张婷
周艳
王庆勇
宗金宝
杨姣姣
王志荣
金亚珉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Basic Medical Sciences of CAMS and PUMC
Original Assignee
Institute of Basic Medical Sciences of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Basic Medical Sciences of CAMS and PUMC filed Critical Institute of Basic Medical Sciences of CAMS and PUMC
Publication of WO2024139647A1 publication Critical patent/WO2024139647A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Definitions

  • the HPV16 DNA vaccine plasmid provided by the present invention contains an E6 antigen gene which is obtained by modifying the amino acid sequence encoded by the wild-type HPV16 E6 gene (GenBank ID: KP677555.1), and the modification method is as follows: two HLA-A2 restricted epitopes (i.e., aa.22-31 and aa.42-60 epitope peptides of the wild-type E6 protein) are inserted between aa.63 and 64 within the second zinc finger binding region (aa.63-66) of the wild-type E6 protein, and the N-terminus, C-terminus and the two epitopes are connected using AAY linkers.
  • the technical solution provided by the present invention also includes an mRNA obtained by transcribing and modifying the nucleotides of SEQ ID No.1.
  • the technical solution provided by the present invention also includes an mRNA obtained by transcribing and modifying the nucleotide fusion gene of SEQ ID No.1 and SEQ ID No.2.
  • Another technical solution of the present invention includes a eukaryotic expression plasmid containing the fusion antigen gene shown in SEQ ID No.1.
  • the HSP70 gene can be further fused downstream of the fusion antigen gene shown in SEQ ID No.1 in the plasmid, and preferably the HSP70 gene is a human HSP70 gene.
  • the plasmid contains an immunostimulatory sequence and constituent elements of a eukaryotic expression vector, and the elements include but are not limited to a replication origin, a resistance gene, a multiple cloning site, a Kozak sequence, a promoter, an enhancer, an intron, a tailing signal, a fluorescent marker gene, and a universal sequencing primer binding site, and the sequences of these elements are known sequences.
  • the present invention also provides a recombinant Escherichia coli, which is obtained by introducing the HPV16 DNA vaccine plasmid of the present invention into Escherichia coli.
  • the present invention also provides a recombinant virus, which is prepared using the HPV16 DNA vaccine plasmid of the present invention or the fusion antigen gene of the present invention.
  • the present invention also provides a cell, which is obtained by introducing the HPV16 DNA vaccine plasmid of the present invention into a host cell, or by infecting a host cell with the recombinant virus of the present invention.
  • HPV16 DNA vaccine preparation in addition to the vaccine plasmid, also includes at least one of an adjuvant, a carrier, a diluent or an excipient.
  • Figure 1 is a plasmid map of Example 1 of the present invention.
  • Figure 2 is the copy number and yield detection of pISS14-16E6E7H and pVax1-16E6E7H plasmids in Example 2 of the present invention.
  • Figure 3 is the expression detection of pISS14-16E6E7H in Example 3 of the present invention.
  • Figure 4 is a comparison of the activity of T cell responses inducing IFN- ⁇ secretion by the wild-type w16E6E7 fusion gene and the optimized 16E6E7 fusion gene of Example 4 of the present invention. ***: P ⁇ 0.001.
  • Figure 5 is a comparison of the activity of T cell responses inducing IFN- ⁇ secretion by pISS14-16E6E7 and pISS14-16E6E7H of Example 5 of the present invention. ***: P ⁇ 0.001.
  • Figure 6 is a comparison of the activity of T cell responses inducing specific IFN- ⁇ secretion by pVax1-16E6E7H and pISS14-16E6E7H of Example 6 of the present invention. ***: P ⁇ 0.001.
  • Figure 7 is a comparison of the activity of T cell responses inducing specific IFN- ⁇ secretion by mixed immunization with pISS14-16E6H and pISS14-16E7H and immunization with pISS14-16E6E7H alone in Example 7 of the present invention. *: P ⁇ 0.05.
  • pISS14-16E7H The 16E7 antigen gene shown in SEQ ID No.8 and the HSP70 gene shown in SEQ ID No.2 were inserted between the KpnI restriction site and the XhoI restriction site of the pISS14 plasmid. The fusion gene was constructed by gene synthesis and loaded into pISS14 after double enzyme digestion. The obtained pISS14-16E7H plasmid map is shown in Figure 1H.
  • Example 4 Comparison of the activity of wild-type w16E6E7 fusion gene and optimized 16E6E7 fusion gene in inducing IFN- ⁇ secretion in T cell responses
  • mice Female C57BL/6 mice aged 6-8 weeks were randomly divided into 3 groups, 4 mice in each group, 1 of which was the pISS14 control group, and the other two groups were pISS14-16E6E7 and pISS14-16E6E7H immunization groups. After the mice were anesthetized by intraperitoneal injection of pentobarbital (75 mg/kg), they were immunized intramuscularly. 10 ⁇ g of each plasmid was immunized. Immediately after injection, two needle electrodes were used to perform electroporation at the injection site (100 V, 50 ms; 100 ms interval; 4 times). Immunization was performed twice, with an interval of 10 days. Mouse spleen lymphocytes were obtained 7 days after the second immunization, and ELISPOT detection was performed using the Mouse IFN- ⁇ ELISPOT kit (BD, 551083). The detection method was as described in Example 4.
  • Example 7 Comparison of the activity of T cell responses inducing IFN- ⁇ secretion by mixed immunization with vaccines containing 16E6H and 16E7H genes and immunization with 16E6E7H fusion antigen gene vaccine
  • mice Female C57BL/6 mice aged 6-8 weeks were randomly divided into 4 groups, 4 mice in each group, 1 of which was the pISS14 control group, and the other 3 groups were the pISS14-16E6H (10 ⁇ g) and pISS14-16E7H (10 ⁇ g) mixed immunization group, pISS14-16E6E7H (20 ⁇ g) group and pISS14-16E6E7H (30 ⁇ g) group.
  • mice were anesthetized by intraperitoneal injection of pentobarbital (75mg/kg), the mice were immunized intramuscularly.
  • two needle electrodes were used to perform electroporation at the injection site (100V, 50ms; interval 100ms; 4 times).
  • each mouse was subcutaneously inoculated with 7.5 ⁇ 104 HPV16 E6E7-positive tumor cell line TC-1.
  • the tumor growth was recorded by visual inspection and palpation, and the observation was performed twice a week.
  • the results are shown in Figure 8.
  • the pISS14-16E6E7H immunization group had no tumors at 45 days after inoculation, while the pISS14 control group had all tumors within 2 weeks.
  • the results showed that pISS14-16E6E7H immunization could induce an immune protective response in the body, effectively reject the subsequently inoculated tumor cells, and completely prevent the formation of transplanted tumors.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un vaccin à ADN de papillomavirus humain de type 16 et son utilisation, qui se rapportent au domaine technique de la biologie. Un gène d'antigène de la présente invention est un gène de fusion de protéine E6 et protéine E7 de papillomavirus humain de type 16 optimisé, et un gène de protéine 70 de choc thermique humain est en outre fusionné en aval de celui-ci. Un plasmide vaccinal comprend en outre une origine de réplication et une séquence immunostimulatrice à base de motif CpG. Le vaccin à ADN de papillomavirus humain de type 16 décrit peut induire une réponse immunitaire cellulaire spécifique d'un antigène E6 et E7 de HPV16 au moyen d'une immunisation par électroporation par injection intramusculaire. Le vaccin à ADN peut être utilisé pour prévenir et traiter une infection par le HPV16, et traiter des lésions précancéreuses associées à une infection et des tumeurs malignes.
PCT/CN2023/128073 2022-12-26 2023-10-31 Vaccin à adn de papillomavirus humain de type 16 et son utilisation Ceased WO2024139647A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211677271.1 2022-12-26
CN202211677271 2022-12-26

Publications (1)

Publication Number Publication Date
WO2024139647A1 true WO2024139647A1 (fr) 2024-07-04

Family

ID=91608160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/128073 Ceased WO2024139647A1 (fr) 2022-12-26 2023-10-31 Vaccin à adn de papillomavirus humain de type 16 et son utilisation

Country Status (2)

Country Link
CN (1) CN118256534A (fr)
WO (1) WO2024139647A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119139462A (zh) * 2024-11-20 2024-12-17 山东省成体细胞产业技术研究院有限公司 一种携带car结构的hpv疫苗、制备方法及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1271389A (zh) * 1997-07-18 2000-10-25 康诺特实验室有限公司 编码呼吸道合胞病毒的g蛋白的核酸疫苗
CN101063142A (zh) * 2006-04-30 2007-10-31 中国医学科学院基础医学研究所 人乳头瘤病毒16型dna疫苗和基因佐剂及其应用
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
CN104593330A (zh) * 2015-01-19 2015-05-06 中国科学院微生物研究所 含有a型流感特异性启动子的重组293t细胞及其应用
CN109862939A (zh) * 2016-06-03 2019-06-07 埃特彼塞斯公司 用于治疗人乳头瘤病毒(hpv)相关疾病的组合物和方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1271389A (zh) * 1997-07-18 2000-10-25 康诺特实验室有限公司 编码呼吸道合胞病毒的g蛋白的核酸疫苗
CN101063142A (zh) * 2006-04-30 2007-10-31 中国医学科学院基础医学研究所 人乳头瘤病毒16型dna疫苗和基因佐剂及其应用
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
CN104593330A (zh) * 2015-01-19 2015-05-06 中国科学院微生物研究所 含有a型流感特异性启动子的重组293t细胞及其应用
CN109862939A (zh) * 2016-06-03 2019-06-07 埃特彼塞斯公司 用于治疗人乳头瘤病毒(hpv)相关疾病的组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI YI-JIE, CHEN KAI-XU,ZHUANG SHU-ZHEN, MA ZHENG-HAI, ZHANG FU-CHUN: "Anti-tumor chimeric DNA vaccines based on the expression of HPV-16 E7/E6 epitope genetically fused with the HSP 70N", vol. 25, no. 7, 1 July 2009 (2009-07-01), pages 606 - 609, XP093185678 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119139462A (zh) * 2024-11-20 2024-12-17 山东省成体细胞产业技术研究院有限公司 一种携带car结构的hpv疫苗、制备方法及其应用

Also Published As

Publication number Publication date
CN118256534A (zh) 2024-06-28

Similar Documents

Publication Publication Date Title
KR102351555B1 (ko) Hpv 및 관련 질환용 면역 증강 치료 백신
JP4799789B2 (ja) ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子
RU2509570C2 (ru) Вакцинная композиция, пригодная при инфекциях hpv и вирусом гепатита в, и способ ее получения
US20110158952A1 (en) Compositions and methods for treating human papillomavirus-mediated disease
CN115197965A (zh) Hpv疫苗
IL199939A (en) Papillomavirus e2 polypeptide for use for vaccination
CN107188966A (zh) 一种乳头瘤病毒嵌合蛋白及其用途
KR102715320B1 (ko) 신형 hpv 치료용 핵산 백신
Massa et al. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein
CN103864936B (zh) Hpv18型l2ne7e6融合蛋白基因、表达载体、方法、菌株和用途
CN102286104B (zh) Hpv6型l2n120e7e6融合蛋白基因、表达载体、方法、菌株和用途
CN101808658A (zh) 细胞穿透肽及其与具有治疗作用的生物分子相融合的用途
WO2024139647A1 (fr) Vaccin à adn de papillomavirus humain de type 16 et son utilisation
EP2377879A1 (fr) Protéines de fusion HPV E7 à terminaison N
WO2019101062A9 (fr) Vaccin recombiné et son application
CN101735310B (zh) Hpv融合蛋白、基因、载体、菌株、制备方法及用途
CN114106115B (zh) 一种腺病毒载体重组新冠病毒b.1.351变异株疫苗及其应用
CN114539363B (zh) 一种c端改造的人乳头瘤病毒11型l1蛋白及其用途
CN100393878C (zh) 疫苗
Panahi et al. Development of multiepitope therapeutic vaccines against the most prevalent high-risk human papillomaviruses
EP3562504B1 (fr) Vaccin à adn comprenant un polynucléotide codant pour une protéine de fusion qui comprend une séquence signal de protéine végétale
US10329328B2 (en) HPV-related fusion protein and applications thereof
Zhao et al. Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18
JP2021180677A (ja) 免疫療法における使用のためのポリエピトープ構築物
US8715681B2 (en) Minimal motifs of linear B-cell epitopes in L1 protein from human papillomavirus type 58 and their applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23909580

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE